Insights - Exelixis (EXEL) on Monday announced positive top-line results from a phase 3 trial of the MEK inhibitor cobimetinib in combination with Zelboraf (vemurafenib) in untreated patients with melanoma harboring … Continue Reading
Read NowInsights - The FDA has informed Salix Pharmaceuticals (SLXP) that Relistor (methylnaltrexone bromide) can be approved for the treatment of constipation in patients taking opioids for chronic non-cancer … Continue Reading
Read NowRecap - Great news for longtime PropThink readers on Monday morning – BioDelivery Sciences (BDSI) announced positive results from the second of two phase 3 studies testing BEMA-Buprenorphine in chronic pain … Continue Reading
Read NowInsights - Lexicon Pharmaceuticals (LXRX) will partner with JDRF (Juvenile Diabetes Research Foundation) for a phase 2 study of LX4211 in younger Type 1 Diabetes (T1D) patients (<30 … Continue Reading
Read NowInsights - Celgene (CELG) said on Wednesday morning that a phase 3 trial of Otezla, the company’s oral inhibitor of phosphodiesterase 4 (PDE4) already approved in active psoriatic … Continue Reading
Read NowInsights - Anacor (ANAC) received FDA approval for the antifungal Kerydin on Tuesday, setting it and the larger Valeant (VRX) up for a marketing battle.
Read NowInsights - Following an end-of-phase 2 meeting with the FDA, Synergy Pharmaceuticals (SGYP) will begin two phase 3 studies of plecanatide, the company’s lead drug candidate, in Irritable … Continue Reading
Read Now
